FindTrial
Sign In

Phase II clinical study in patients with Parkinson's disease.

Pharmacokinetic study of HP-3000 in patients with Parkinson's disease.

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221631
Enrollment
Unknown
Registered
2011-10-25
Start date
2011-10-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

investigational material(s) Generic name etc : HP-3000 (ropinirole hydrochloride patch) INN of investigational material : Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administra

Sponsors

Hisamitsu Pharmaceutical Co., Inc.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Patients diagnosed with Parkinson's disease in stages 1 to 4 on the modified Hoehn & Yahr scale

Exclusion criteria

Exclusion criteria: - Patients with a history of hypersensitivity to ropinirole - Patients with clinically significant renal impairment or hepatic dysfunction - Patients with skin disease at the application site for the investigational drug that may hinder its evaluation or patients receiving any treatment that may interfere with evaluation of the drug

Design outcomes

Primary

MeasureTime frame
Efficacy, safety, and pharmacokinetics—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026